The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Targeting hyperactivation of the AKT survival pathway to overcome therapy resistance of melanoma brain metastases.
Friedegund Elke Meier
No relevant relationships to disclose
Andrea Forschner
No relevant relationships to disclose
Bernhard Klumpp
No relevant relationships to disclose
Keith T. Flaherty
No relevant relationships to disclose
Juergen Bernd Honegger
No relevant relationships to disclose
Maria Witte
No relevant relationships to disclose
Antje Bornemann
No relevant relationships to disclose
Reinhard Dummer
No relevant relationships to disclose
Juergen Bauer
No relevant relationships to disclose
Ghazaleh Tabatabai
No relevant relationships to disclose
Benjamin Weide
No relevant relationships to disclose
Thomas K. Eigentler
No relevant relationships to disclose
Dirk Schadendorf
No relevant relationships to disclose
Leticia Quintanilla-Fend
No relevant relationships to disclose
Heike Niessner
No relevant relationships to disclose
Claus Garbe
No relevant relationships to disclose